STERIS plc provides infection prevention and other procedural products and services worldwide.
Excellent balance sheet with solid track record.
Share Price & News
How has STERIS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: STE's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: STE exceeded the US Medical Equipment industry which returned 12.8% over the past year.
Return vs Market: STE exceeded the US Market which returned 4.1% over the past year.
Price Volatility Vs. Market
How volatile is STERIS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIs Now An Opportune Moment To Examine STERIS plc (NYSE:STE)?
1 month ago | Simply Wall StA Rising Share Price Has Us Looking Closely At STERIS plc's (NYSE:STE) P/E Ratio
1 month ago | Simply Wall StDoes STERIS (NYSE:STE) Deserve A Spot On Your Watchlist?
Is STERIS undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: STE ($157.48) is trading above our estimate of fair value ($97.84)
Significantly Below Fair Value: STE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: STE is good value based on its PE Ratio (32.8x) compared to the Medical Equipment industry average (45.7x).
PE vs Market: STE is poor value based on its PE Ratio (32.8x) compared to the US market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: STE is poor value based on its PEG Ratio (18x)
Price to Book Ratio
PB vs Industry: STE is overvalued based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (3.6x).
How is STERIS forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STE's forecast earnings growth (1.8% per year) is below the savings rate (2.2%).
Earnings vs Market: STE's earnings (1.8% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: STE's earnings are forecast to grow, but not significantly.
Revenue vs Market: STE's revenue (4.4% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: STE's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STE's Return on Equity is forecast to be low in 3 years time (13.4%).
How has STERIS performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STE has high quality earnings.
Growing Profit Margin: STE's current net profit margins (13.4%) are higher than last year (10.9%).
Past Earnings Growth Analysis
Earnings Trend: STE's earnings have grown significantly by 28.1% per year over the past 5 years.
Accelerating Growth: STE's earnings growth over the past year (34%) exceeds its 5-year average (28.1% per year).
Earnings vs Industry: STE earnings growth over the past year (34%) exceeded the Medical Equipment industry 7.3%.
Return on Equity
High ROE: STE's Return on Equity (12%) is considered low.
How is STERIS's financial position?
Financial Position Analysis
Short Term Liabilities: STE's short term assets ($1.2B) exceed its short term liabilities ($503.6M).
Long Term Liabilities: STE's short term assets ($1.2B) do not cover its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: STE's debt to equity ratio (30.2%) is considered satisfactory.
Reducing Debt: STE's debt to equity ratio has reduced from 57.9% to 30.2% over the past 5 years.
Debt Coverage: STE's debt is well covered by operating cash flow (57.5%).
Interest Coverage: STE's interest payments on its debt are well covered by EBIT (15x coverage).
What is STERIS's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: STE's dividend (0.94%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.75%).
High Dividend: STE's dividend (0.94%) is low compared to the top 25% of dividend payers in the US market (4.73%).
Stability and Growth of Payments
Stable Dividend: STE is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: STE is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: STE is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of STE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Walt Rosebrough (65yo)
Mr. Walter M. Rosebrough, Jr., also known as Walt, has been the Chief Executive Officer and President of STERIS plc since October 1, 2007. Mr. Rosebrough leads STERIS’ management team, assists the Board in ...
CEO Compensation Analysis
Compensation vs Market: Walt's total compensation ($USD5.98M) is below average for companies of similar size in the US market ($USD11.86M).
Compensation vs Earnings: Walt's compensation has been consistent with company performance over the past year.
|CEO, President & Director||12.58yrs||US$5.98m||0.086% $11.4m|
|Senior VP & CFO||12.17yrs||US$2.25m||0.061% $8.2m|
|Senior VP & Chief Operating Officer||1.75yrs||US$2.15m||0.027% $3.6m|
|Senior VP||6.83yrs||US$1.46m||0.034% $4.5m|
|Chief Accounting Officer||3.33yrs||no data||0.0088% $1.2m|
|Senior Director of Investor Relations||no data||no data||no data|
|Chief Compliance Officer & Senior VP||12.17yrs||no data||0.021% $2.7m|
|Senior Director of Corporate Communications||no data||no data||no data|
|VP & Chief HR Officer||2.67yrs||no data||0.0096% $1.3m|
|Senior Vice President of Infection Prevention Technologies||6.25yrs||US$2.19m||no data|
Experienced Management: STE's management team is seasoned and experienced (6.5 years average tenure).
|CEO, President & Director||12.58yrs||US$5.98m||0.086% $11.4m|
|Independent Director||12.08yrs||US$294.98k||0.036% $4.8m|
|Independent Director||9.83yrs||US$299.96k||0.0079% $1.1m|
|Independent Chairman of the Board||1.83yrs||US$399.85k||0.026% $3.5m|
|Independent Director||16.58yrs||US$280.38k||0.052% $6.9m|
|Independent Director||15.17yrs||US$279.81k||0.011% $1.4m|
|Independent Director||4.5yrs||US$294.96k||no data|
|Independent Director||2yrs||US$339.99k||no data|
Experienced Board: STE's board of directors are seasoned and experienced ( 11 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
STERIS plc's company bio, employee growth, exchange listings and data sources
- Name: STERIS plc
- Ticker: STE
- Exchange: NYSE
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$13.356b
- Shares outstanding: 84.81m
- Website: https://www.steris.com
Number of Employees
- STERIS plc
- 70 Sir John Rogerson’s Quay
- Dublin 2
- D02 R296
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|STE||NYSE (New York Stock Exchange)||Yes||New Common Stock||US||USD||Jun 1992|
|2TG||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||Jun 1992|
|0XI8||LSE (London Stock Exchange)||Yes||New Common Stock||GB||USD||Jun 1992|
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier products, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization services through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/26 04:04|
|End of Day Share Price||2020/05/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.